multiplesclerosisnewstoday.com

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

The Web's Daily Resource for Multiple Sclerosis News
  1. leukocytesI rolled onto the neurology ward of the hospital that has been dealing with my disease from the beginning. The nurses, whom I’ve met innumerable times, opened with their normal jolly, “How are you?” I can never resist, “Well, I have got MS!” It was 8 in the morning. I’d turned up for my twice-yearly […]

    The post Stop in the Name of Leukocytes appeared first on Multiple Sclerosis News Today.

  2. forumsAbout a year and a half ago, Multiple Sclerosis News Today introduced a forums section. It’s a great place to post a question or comment about MS, or to answer someone else’s question. I’m one of the forum moderators, along with John Connor. I get around better than John, but John is a stand-up comic […]

    The post Have You Joined the Conversations in Our MS Forums? appeared first on Multiple Sclerosis News Today.

  3. MetP Pharma patentMetP Pharma‘s patent application for a new method to treat demyelinating and neuroinflammatory diseases, including multiple sclerosis (MS), has been approved by the United States Patent and Trademark Office (USPTO). The patent, titled “Treatment of Demyelinating Diseases” (U.S. Appl. No. 16/506,830), is valid until 2039, and covers the use of a steroid hormone, such as testosterone, […]

    The post MetP Pharma Awarded US Patent for Potential Remyelination Therapy appeared first on Multiple Sclerosis News Today.

  4. Canada and MavencladPeople with relapsing-remitting multiple sclerosis (RRMS) across Canada are a major step closer to having access to EMD Serono’s Mavenclad (cladribine). EMD Serono, known as Merck KGaA outside of North America, has finish negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) that oversees new drugs coming in, and signed a letter of intent to an agreement that […]

    The post EMD Serono, Canada Sign Agreement for Public Health Plan Funding of Mavenclad for RRMS appeared first on Multiple Sclerosis News Today.

  5. smoldering lesionsEditor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by two forum topics about silent inflammation from August 2019. Have an experience you want to share? Leave a comment here or at […]

    The post Need to Know: MS and Smoldering Lesions appeared first on Multiple Sclerosis News Today.

 
 

Follow Us on Twitter

Follow Us On Twitter - Image